Skip to content
Search

Latest Stories

Nurse dies after using weight-loss drug tirzepatide

Nurse dies after using weight-loss drug tirzepatide

She had bought a prescription for the weight-loss drug through a registered online pharmacy

A 58-year-old nurse from North Lanarkshire, Scotland, has reportedly died after taking the weight-loss drug tirzepatide, which was recently approved for use on the NHS.

Susan McGowan died from multiple organ failure, septic shock and pancreatitis, with the use of the Eli Lilly drug listed as a contributing factor on her death certificate, according to the BBC.


She had taken two low-dose injections of tirzepatide, known by the brand name Mounjaro, over a two-week period before her death on 4 September. Her death is thought to be the first in the U.K. officially linked to the drug.

McGowan, who had worked for over 30 years as a nurse at University Hospital Monklands in Airdrie, purchased a prescription for the drug through a registered online pharmacy.

A few days after her second injection, McGowen began experiencing severe stomach pains and sickness. She went to A&E at Monklands - where her colleagues tried to save her life.

Within days, her kidneys failed, and she fell into a coma as her other organs began to fail.

Weight-loss drugs and safety concerns

Tirzepatide belongs to a group of weight-loss drugs known as GLP-1 receptor agonists that lower appetite by making people feel fuller for longer.

It was approved for use as a weight-loss aid in the UK in 2023 by the Medicines and Healthcare products Regulatory Agency (MHRA).

Between January and May 2024, there were 208 reports about tirzepatide on the Yellow Card Scheme, including 31 serious reactions and one suspected death of a man in his sixties.

However, MHRA chief safety officer Dr. Alison Cave stated that, based on the current evidence, the benefits of GLP-1 receptor agonists outweigh the potential risks when used for their licensed purposes.

She told the BBC: “Patient safety is our top priority and no medicine would be approved unless it met our expected standards of safety, quality and effectiveness.

“We have robust, safety monitoring and surveillance systems in place for all healthcare products,” she said.

Dr Cave offered her "sincere sympathies" to McGowan’s family on behalf of the organisation.

A spokesperson from Eli Lilly commented that Mounjaro was approved based on "extensive assessment of the benefits and risks of the medicine" and that they provide information about the benefits and risks of all their medicines to regulators worldwide to ensure the latest information is available for prescribers.

Semaglutide, a similar GLP-1 receptor agonist, is sold under the brand names Wegovy and Ozempic and is also used for weight loss.

Manufactured by Novo Nordisk, this drug has been linked to 23 suspected deaths in the UK since 2019 via the Yellow Card Scheme.

 

 

 

More For You

Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Asda pharmacy launches UK’s first adult earache service

Asda makes ear health more accessible for everyone

gettyimages

Asda pharmacy launches £25 adult earache service

British supermarket chain Asda has launched the “UK’s first” adult earache service, aiming to reduce the burden on NHS services by eliminating the need for a GP appointment.

Priced at £25, the service allows patients aged 18 and over to book same-day appointments with qualified Asda pharmacists at any of its 226 pharmacies in England.

Keep ReadingShow less
Dr Penelope Dash new chair of NHS England

Dr Penny Dash is currently the chair of the NHS North West London Integrated Care Board

parliamentlive

Dr Penelope Dash appointed as new chair of NHS England

Dr Penny Dash has been appointed as the next chair of NHS England following an open public appointment process.

She will succeed Richard Meddings, who is set to step down next month, and her four-year term begins on April 1, 2025.

Keep ReadingShow less